Integrated analyses reveal IDO1 as a prognostic biomarker coexpressed with PD-1 on tumor-associated macrophages in esophageal squamous cell carcinoma
This study identifies IDO1 as an independent prognostic indicator of OS in patients with ESCC, reveals a compelling connection of IDO1, PD-1, and TAMs, and explores the sensitivity of patients with high IDO1 expression to chemotherapeutic drugs and their resistance to IC blockade. These findings open new avenues for potential targets in ESCC immunotherapy.
Authors
- Xiaoxuan Sun (ORCID: https://orcid.org/0000-0002-4909-1295)
- Jie Gao (ORCID: https://orcid.org/0000-0002-4648-7956)
- Lingxiong Wang (ORCID: https://orcid.org/0000-0002-8973-8911)
- Liping Zhang (ORCID: https://orcid.org/0000-0002-6702-8345)
- Juan Yang (ORCID: https://orcid.org/0000-0002-0850-679X)
- Qing Zhou
- Jinying Zhang (ORCID: https://orcid.org/0000-0002-2634-6275)
- Fan Yin (ORCID: https://orcid.org/0000-0001-5460-1117)
- Yaojun Peng (ORCID: https://orcid.org/0000-0003-3652-2452)
- Zhu Haiyan
- Qiyan Wu
- Yanju Yu
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Chinese PLA General Hospital (CN)
- Tianjin Fourth Hospital (CN)
- Chinese People's Liberation Army (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.3389/fphar.2024.1466779
- Citations
- 7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.98